Gemcitabine (GEM) alone and GEM‐based chemotherapy are the preferred regimens for
treating advanced unresectable and metastatic pancreatic cancer (PC). However, these …

Pancreatic cancer is one of the most lethal types of cancer in the world. The incidence of
pancreatic cancer increases each year with no significant decrease in mortality. Pancreatic …

The efficacy of gemcitabine (GEM), a standard treatment agent for pancreatic cancer, is
insufficient because of primary or acquired resistance to this drug. Patients with tumors …

Pancreatic ductal adenocarcinoma (PDA) remains one of the most lethal malignancies in the
world, often diagnosed at an advanced stage, resistant to conventional chemotherapy and …

Pancreatic ductal adenocarcinoma (PDAC), generally known as pancreatic cancer (PC),
ranks the fourth leading cause of cancer-related deaths in the western world. While the …

Gemcitabine (GEM) is the standard treatment for advanced/metastatic pancreatic cancer.
However, there is a substantial subset of patients in whom the efficacy of GEM, when used …

Pancreatic cancer is often unresectable at diagnosis, and chemotherapy using gemcitabine
is now the standard treatment for advanced pancreatic cancer. However, acquired …

Due to its rapid progression, metastasis and resistance to chemotherapy, pancreatic cancer
is one of the most malignant tumor types to affect the digestive system. Gemcitabine …

Purpose: Gemcitabine is most commonly used for pancreatic cancer. However, the
molecular features and mechanisms of the frequently occurring resistance remain unclear …

Objectives: Gemcitabine is the standard chemotherapeutic agent for pancreatic cancer.
Nevertheless, the prognosis of pancreatic cancer patients is still poor. Evaluating the …